EA
PCVX icon

Ellsworth Advisors’s Vaxcyte PCVX Stock Holding History

Ellsworth Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-8,060
Closed -$506K – 193
2023
Q4 		$506K Buy
8,060
+207
+3% +$10.8K 0.16% 107
2023
Q3 		$365K Buy
+7,853
New +$387K 0.13% 133

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ellsworth Advisors's PCVX Position: Q1 2024 in Review

Ellsworth Advisors sold out of Vaxcyte (PCVX) in Q1 2024, closing a stake of 8,060 shares — an estimated $506K sold.

Ellsworth Advisors first reported a position in PCVX in Q3 2023 and held it in 2 quarters. The position peaked at $506K in Q4 2023. 251 funds tracked by Wall St. Rank hold PCVX as of Q1 2024.

  • Ellsworth Advisors reported no remaining Vaxcyte position as of Q1 2024 after selling out during the quarter.
  • Ellsworth Advisors sold 8,060 Vaxcyte shares in Q1 2024, an estimated $506K.
  • Ellsworth Advisors first reported a position in Vaxcyte in Q3 2023 and held it in 2 quarters.
  • Ellsworth Advisors's Vaxcyte position peaked at $506K in Q4 2023.
  • 251 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2024.

Based on Ellsworth Advisors's 13F filing for Q1 2024, filed 15 Apr 2024.